Indication

Prevention of bronchospasm with chronic bronchitis

Prevention of bronchospasm with chronic bronchitis refers to prophylactic management aimed at averting acute, reversible airway smooth muscle constriction in patients affected by chronic bronchitis, a primary phenotype of chronic obstructive pulmonary disease (COPD). Read more about Prevention of bronchospasm with chronic bronchitis

16 drugs 16 manufacturers

Advertisement

Drugs that treat it

Common Prevention of bronchospasm with chronic bronchitis therapies.

Showing 1–9 of 16 drugs

ROFLUMILAST

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
Major Pharamceuticals

ROFLUMILAST

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
CAMBER PHARMACE

ROFLUMILAST

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
MICRO LABS USA,

ROFLUMILAST

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
SOLCO HEALTHCAR

ROFLUMILAST

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
AHP

ROFLUMILAST

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
BRYANT RANCH PR

ROFLUMILAST

PHOSPHODIESTERASE-4 (PDE4) INHIBITORS·PREVENTION OF BRONCHOSPASM WITH CHRONIC BRONCHITIS
AUROBINDO PHARM
Filter & compare in the drug finder →Opens the drug finder with Prevention of bronchospasm with chronic bronchitis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevention of bronchospasm with chronic bronchitis.

Prevention of bronchospasm with chronic bronchitis refers to prophylactic management aimed at averting acute, reversible airway smooth muscle constriction in patients affected by chronic bronchitis, a primary phenotype of chronic obstructive pulmonary disease (COPD).

The condition primarily impacts the lower respiratory system, predominantly in adults with prolonged exposure to inhaled irritants such as tobacco smoke.

Pathophysiologically, persistent mucosal inflammation, goblet cell hyperplasia, and excessive mucus hypersecretion lead to airway hyperresponsiveness and structural narrowing.

In this state, recurrent bronchospasms precipitate sudden episodes of airflow limitation, clinically characterized by acute exacerbation of dyspnea, wheezing, chest tightness, and severe cough.

Personalize your experience

Follow Prevention of bronchospasm with chronic bronchitis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it